The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
A. D. Norden
No relevant relationships to disclose
S. Hammond
No relevant relationships to disclose
J. Drappatz
No relevant relationships to disclose
S. Phuphanich
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - EMD Serono; Genentech
Honoraria - Genentech; Merck
E. Wong
No relevant relationships to disclose
S. R. Plotkin
No relevant relationships to disclose
G. J. Lesser
No relevant relationships to disclose
J. J. Raizer
No relevant relationships to disclose
T. Batchelor
No relevant relationships to disclose
E. C. Quant
Consultant or Advisory Role - Genentech
R. Beroukhim
Consultant or Advisory Role - Novartis
Stock Ownership - AstraZeneca
T. J. Kaley
No relevant relationships to disclose
A. Muzikansky
No relevant relationships to disclose
A. S. Ciampa
No relevant relationships to disclose
L. M. Doherty
No relevant relationships to disclose
K. H. Smith
No relevant relationships to disclose
M. Gerard
No relevant relationships to disclose
C. Sceppa
No relevant relationships to disclose
P. Y. Wen
Research Funding - Novartis